GSK/Agenus vaccine shows only 'modest' malaria protection in infants
This article was originally published in Scrip
Executive Summary
Disappointingly, the latest Phase III results for GlaxoSmithKline's malaria vaccine candidate, Mosquirix (RTS,S), have demonstrated a more 'modest' reduction in the incidence of the disease than previously reported from the same trial.